AFP and hepatocellular carcinoma: <h4>Background</h4>To investigate the value of AFP combined with degamma-carboxylprothrombin (DCP), vitamin K absence or antagonist-II (PIVKA) in predicting the efficacy of transhepatic arterial chemoembolisation (TACE).<h4>Methods</h4>The clinical data of 69 patients with hepatocellular carcinoma (HCC) who received TACE at our hospital between March 2020 and December 2024 were retrospectively analysed.